Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study is a prospective single-arm phase II study to evaluate the efficacy and safety of
Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed
standard therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital